Glioblastoma multiforme is the most aggressive form of human brain tumor, which has no effective cure. Previously, we have demonstrated that overexpression of the C-terminal fragment of the human telomerase reverse transcriptase (hTERTC27) inhibits the growth and tumorigenicity of human cervical cancer HeLa cells. In this study, the therapeutic effect and molecular mechanisms of hTERTC27-mediated cancer gene therapy were further explored in vivo in established human glioblastoma xenografts in nude mice. We showed that intratumoral injection of adeno-associated virus carrying hTERTC27 (rAAV-hTERTC27) is highly effective in reducing the growth of the subcutaneously transplanted glioblastoma tumors. Histological analyses showed that rAAV-hTERTC27 treatment leads to profound necrosis, apoptosis, infiltration of polymorphonuclear neutrophils and reduced microvessel density in the tumor samples. To study the molecular mechanism of rAAV-hTERTC27-mediated antitumor effects, we analyzed the global gene expression profiles of the rAAV-hTERTC27-treated tumor tissues and cell line as compared with that of the control rAAV-green fluorescent protein-treated samples by DNA microarray. Our results suggest that hTERTC27 exerts its effect through complex mechanisms, which involve genes regulating apoptosis, cell adhesion, cell cycle, immune responses, metabolism, signal transduction, transport, transcription and telomere maintenance.
Introduction
Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults. In Europe and North America, the annual incidence is in the range of 2-3 cases per 100 000 population, representing about 30% of all intracranial neoplasms.
1,2 GBM is notorious for its highly invasive behavior and patients without therapy usually die within 3 months. 3 Currently, the best treatment for GBM involves a combination of resection, chemotherapy and radiotherapy. Nevertheless, even with these multiple treatment modalities, the median survival rate is still less than 1 year. 4, 5 Therefore, the development of novel and effective therapeutic opportunities is of utmost importance in order to combat this deadly disease.
Recently, the use of telomerase as a target for treating glioblastoma has aroused considerable interest among neuro-oncologists, primarily because secondary glioblastomas, which progress from low-grade gliomas, invariably express high levels of telomerase. 6 Telomerase is a specialized ribnucleoprotein complex responsible for the maintenance of telomeres, which consist of tandem repeats of the sequence (TTAGGG) n at the chromosome ends in humans. 7, 8 Structurally, telomerase is made up of the telomerase RNA (hTR or hTERC) and the catalytic protein subunit of the telomerase reverse transcriptase (hTERT). In most human somatic cells (except germ cells, stem cells, and cells for tissue renewal) telomerase activity is absent and hence telomeres shorten after every cell division. When telomere length becomes sufficiently short, cells will enter senescence and eventually die. However, in 70-95% of all the human cancers, telomerase activity is reactivated, leading to cell immortalization and malignant transformation. [9] [10] [11] The almost universal expression of telomerase in cancers makes it an attractive candidate for targeted gene therapy, especially for glioblastomas in which there are few, if any, treatment alternatives.
Previously, we have shown that a 27 kDa C-terminal polypeptide of hTERT (hTERTC27) is capable of inducing telomere dysfunctions and anaphase chromosome end-to-end fusions in hTERT-positive HeLa cells. 12 Overexpression of hTERTC27 also inhibits HeLa cell growth and tumorigenicity in nude mice xenografts. Importantly, the actions of hTERTC27 are mediated without perturbing the endogenous telomerase activity, thereby minimizing the potential side effects on telomerasepositive reproductive cells and proliferative cells of renewal tissues in antitelomerase therapies. [13] [14] [15] In this study, we further explored the antitumor effect of hTERTC27 by delivering this gene to human GBM cells using adenoassociated virus (AAV). Our results demonstrated that intratumoral injection of recombinant AAV carrying hTERTC27 (rAAV-hTERTC27) is highly potent in inhibiting the growth of human U87-MG glioblastoma cells in athymic nude mice. Histological analyses showed that the effects of hTERTC27 are mediated by increasing necrosis, apoptosis, neutrophil infiltration and decreasing microvessel density in the glioblastoma tissues. Furthermore, microarray studies on the rAAV-hTERTC27-and rAAV-green fluorescent protein (EGFP)-treated GBM tissues and cell line suggested that hTERTC27 works via multiple mechanisms against the GBM cells.
Materials and methods

Cell culture
Human glioblastoma U87-MG cells (ATCC, Rockville, MD) were cultured in minimal essential medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA). The cells were maintained at 371C in 5% CO 2 incubator and passaged at weekly intervals.
Production and purification of recombinant AAV
The cDNAs encoding the 27 kDa C-terminal fragment of hTERT (hTERTC27) and EGFP were obtained by polymerase chain reaction (PCR) using the pCI-neohTERT 12 and pEGFP-N1 (BD Biosciences, San Jose, CA) as templates, respectively. The sequences of the PCR products were confirmed by DNA sequencing. The hTERTC27 and EGFP cDNAs were subcloned into the EcoRI and XhoI sites of the pAM/CAG-WPRE-BGHpolyA plasmid 16, 17 to generate the AAV packaging plasmids, pAM/CAG-hTERTC27 and pAM/CAG-EGFP, respectively (Figure 1) . Structurally, the hTERTC27 protein consists of the C-terminal 251 amino acids (residues 882-1132) of human hTERT. The nuclear export signal (residues 970-981) and the 14-3-3-binding amphipathic helix (residues 1030-1047) responsible for the nuclear translocation of hTERT are included, but all the telomerase RNA-binding domain and most of the conserved reverse transcriptase domains are deleted. 12 Recombinant AAV carrying either hTERTC27 (rAAVhTERTC27) or EGFP (rAAV-EGFP) was produced by transient expression method using human embryonic kidney 293 cells as described earlier. 16, 17 The viruses were purified by HiTrap Heparin column chromatography (Sigma Chemical Co., St Louis, MO) and the viral genome (v.g.) titer was determined by TaqMan real-time PCR (Perkin-Elmer Biosystems, Foster City, CA). The viral stock was concentrated by a centrifugal filter device (Amicon, Millipore, Billerica, MA) and was kept at À801C before use.
Animals
Female BALB/c athymic mice (5-8 weeks old) were purchased from the Charles River Laboratories (Wilmington, MA) and were housed under asceptic conditions and cared for according to the guidelines from the Laboratory Animal Unit of the University of Hong Kong. All experimental protocols were approved by the Department pAM/CAG-EGFP Figure 1 Schematic of AAV packaging plasmids encoding hTERTC27 (pAM/CAG-hTERTC27) and EGFP (pAM/CAG-EGFP). These packaging plasmids include a hybrid CMV enhancer/chicken b-actin (CAG) promoter, a cDNA encoding either hTERTC27 or EGFP, a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and a bovine growth hormone polyadenylation signal (BGH-polyA), which are flanked by two AAV-2 inverted terminal repeats (ITR).
hTERTC27 elicits antitumor effect on glioblastoma SSM Ng et al Subcutaneous human glioblastoma xenografts and intratumoral injection of rAAV-hTERTC27 U87-MG cells in exponential growth phase were harvested and washed twice in phosphate-buffered saline (PBS). The cells were resuspended in PBS at a density of 5 Â 10 7 cells/ml and 0.1 ml (5 Â 10 6 cells) of the cell suspension was then injected subcutaneously into the right flank of each nude mouse. Seven days after subcutaneous tumor cell injection, mice were anesthetized and 1.5 Â 10 11 v.g. of rAAV-hTERTC27 or rAAV-EGFP was injected directly into the tumors at three different locations by a 10-ml micro-syringe (Hamilton, Reno, NV). Tumor size was measured every week by a caliper, and tumor volume (V) was calculated by the formula
, where a and b are the long and short diameters of the tumor, respectively. In compliance with the UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia, mice with tumor burdens 410% of their body weight were killed immediately.
Histological studies and immunohistochemistry rAAV-EGFP-treated and rAAV-hTERTC27 treated U87-MG xenografts were freshly isolated from the nude mice and fixed in 10% buffered formalin. The fixed tissues were dehydrated in a graded series of ethanol and then embedded in paraffin. The tissue blocks were then cut at 5 mm thickness with a microtome. For histological analysis, sections were deparaffinized with xylene, rehydrated in a graded ethanol series, and stained with hematoxylin and eosin (H&E). For immunohistochemistry, the sections were first incubated with a rabbit polyclonal GFP antibody (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 1 h. After washing in PBS, the sections were incubated with a biotinylated goat anti-rabbit secondary antibody for 30 min, followed by streptavidin-horse radish peroxidase solution for 15 min. Finally, immunoreactive cells were detected by a DAB chromogen reagent (Chemicon, Temecula, CA).
Microvessel density
Microvessels in the tumor samples were detected immunohistochemical staining for von Willebrand factor (vWF), a marker for vascular endothelial cells, using a Blood Vessel Staining kit (Chemicon). Briefly, paraffinembedded tumor sections were deparaffinized by xylene, rehydrated by a graded ethanol series, and treated with 0.3% hydrogen peroxide in methanol for 30 min. After washing in PBS for 10 min, the sections were incubated with 5% normal goat serum for 30 min. Excess serum was drained off, and the sections were then incubated with a diluted rabbit anti-vWF polyclonal antibody (1:500) for 2 h in a moist container. After rinsing thoroughly in PBS, the sections were treated with a biotinylated goat antirabbit secondary antibody for 30 min, followed by the streptavidin-horse radish peroxidase solution for 15 min. The presence of the immunoreactive endothelial cells was detected by a DAB chromogen reagent (Chemicon). The sections were counterstained briefly in hematoxylin, dehydrated and mounted. To determine the microvessel density, the microvessels in 10 randomly selected high power fields ( Â 200) in each tumor section were counted, and the data were expressed as mean number of microvessels7s.d. per field.
TUNEL assay
The presence of apoptotic cells in the U87-MG glioblastoma xenografts was detected by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay using the in situ cell death detection kit (POD) (Roche, Indianapolis, IN) according to the procedures recommended by the manufacturer. After addition of the DAB substrate solution, the sections were counterstained by hematoxylin for 5 min, dehydrated, and mounted before observation under a light microscope.
Reverse transcription-PCR U87-MG tumor tissues were disrupted by a Polytron homogenizer (Brinkmann, Germany) and total RNA was harvested using the Trizol reagent (Invitrogen). Firststrand cDNA was synthesized from 1 mg total RNA by the SuperScript III First-Strand cDNA Synthesis System (Invitrogen) according to the manufacturer's instructions. The sequences of the PCR primers for hTERTC27 are:
. The PCRs were carried out with an initial denaturation step of 5 min at 941C followed by 30 cycles of 1 min at 941C, 1 min at 551C and 1min at 721C each 50 ml reaction contained 50 pmol of primers, 20 mM dNTPs and 2.5 U Taq Polymerase (Invitrogen). The PCR products were electrophoresed on 1% ethidium bromide stained agarose gel and visualized by a UV transilluminator.
hTERTC27 elicits antitumor effect on glioblastoma SSM Ng et al
Microarray analysis
Pooled U87-MG tumor samples (n ¼ 3) were freshly isolated from either rAAV-hTERTC27-treated or the control rAAV-EGFP-treated nude mice at day 21 posttreatment and then rapidly frozen in liquid nitrogen. U87-MG cells treated with the same vectors were also harvested at day 21 post-infection. The tumor tissues and transduced cells were homogenized and total RNA was isolated from the tissue homogenates by RNeasy Mini kit (Qiagen, Hilden, Germany). The integrity of the total RNA was analyzed by formaldehyde agarose gel electrophoresis and by an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Only RNA samples with A 260 /A 280 ratio of 1.9-2.0 and with 28S rRNA/18S rRNA ratio approaching 2 to 1 were used for microarray analysis (Affymetrix, Santa Clara, CA). Briefly, double stranded cDNA was first synthesized from total RNA. In vitro transcription was then performed to produce biotinylated cRNA from cDNA. The cRNA was fragemented and mixed with probe array controls, bovine serum albumin and herring sperm DNA. The hybridization mixture was then hybridized to the GeneChip Human Genome U133 set array (Affymetrix, Santa Clara, CA), which contains more than 33 000 well-substantiated genes in the human genome, for 16 h. The array chip was thoroughly washed and then stained sequentially with streptavidin phycoerythrin and biotinylated antistreptavidin antibody. Finally, the array was scanned by the Affymetrix Gene Chip scanner 3000 and the data were analyzed by the GeneChip Operating Software (Affymetrix).
Results
Expression of hTERTC27 and EGFP in human glioblastoma U87-MG cells, respectively, infected with rAAV-hTERTC27 and rAAV-EGFP As AAV infection requires the presence of heparan sulfate proteoglycan and human fibroblast growth factor 1 as a co-receptor, 18 we first tested whether the packaged rAAVhTERTC27 and rAAV-EGFP can successfully infect the human glioblastoma U87-MG cells in vitro. The U87-MG cell line was chosen in this study, because it is one of the most tumorigenic glioblastoma cell lines identified to date. Using reverse transcription(RT)-PCR, PCR products for both hTERTC27 and EGFP with correct sizes were detected, indicating that the viruses are functional and are able to transduce the U87-MG cells (Figure 2a) . The expression of the EGFP protein was further confirmed by detecting the green fluorescent signals in the rAAV-EGFP-infected cells using a fluorescent microscope. At a multiplicity of infection (MOI) of 10 4 , nearly all the infected U87-MG cells displayed strong fluorescent signals (Figure 2b ).
Intratumoral injection of rAAV-hTERTC27 significantly inhibits the growth of the U87-MG xenografts in nude mice To demonstrate the antitumor effect of hTERTC27 in vivo, we first established a glioblastoma xenograft model by implanting U87-MG cells subcutaneously in the right flanks of the nude mice. When the tumor nodules became visible (about 3-5 mm in diameter), PBS, rAAV-EGFP or rAAV-hTERTC27 was injected directly into the tumor and the tumor sizes were continuously monitored on a weekly basis. As shown in Figure 3a , the tumor volumes of the rAAV-hTERTC27-treated mice were markedly smaller than those of the rAAV-EGFP-treated mice 4 weeks after rAAV injection. Five weeks after the rAAV treatment, all the mice in the control PBS and rAAV-EGFP groups were killed because their tumor burdens had already exceeded 10% of their body weight. On the contrary, the mean tumor volume of the rAAVhTERTC27-treated mice was o20% of that of the control mice (Figure 3b ). Our data also showed that rAAV-hTERTC27 treatment could significantly extend the median survival time of the mice from 36-70 days (n ¼ 5, Po0.05) (Figure 3c and Table 1 (Figure 3e ).
rAAV-hTERTC27 treatment leads to necrosis, apoptosis, neutrophil infiltration and reduced microvessel density in U87-MG xenografts To examine how rAAV-hTERTC27 can profoundly inhibit the growth of the U87-MG cells in vivo, we collected the xenograft samples at days 10 and 21 post-AAV treatment and then performed histological and immunohistochemical analyses. As revealed by H&E staining, we consistently observed areas of necrosis in the samples treated with rAAV-hTERTC27 (Figure 4a , right), but not those treated with rAAV-EGFP (Figure 4a, left) . Under high power magnification, infiltration of polymorphonuclear neutrophils (PMNs) was frequently detected in various regions within the rAAV-hTERTC27-injected tumor masses (Figure 4b , right). TUNEL assay also revealed that rAAVhTERTC27, but not rAAV-EGFP, induced prominent cell apoptosis in the tumor samples (Figure 4c and e). Immunohistochemical staining with a polyclonal antibody for an endothelial cell marker, vWF, demonstrated that intratumoral injection of rAAV-hTERTC27 also led to a dramatic reduction in the microvessel density within the tumor vasculature (Figure 4d and e).
rAAV-hTERTC27 treatment induces differential expression of genes involved in complex signaling pathways
To study the molecular mechanism of rAAV-hTERTC27-mediated antitumor effects, we analyzed the global gene expression profile of the rAAV-hTERTC27-injected U87-MG tumor tissues as compared with that of the control rAAV-EGFP-injected tissues by microarray. Genes with fluorescent signal log 2 ratio X1 were considered to be upregulated, whereas those with log 2 ratio pÀ1 were downregulated. The functions of the target genes for hTERTC27 were categorized based on the Gene Ontology items available in SOURCE (http:// genome-www5.stanford.edu/cgi-bin/source/sourceSearch) and GeneCard (http://genome-www.stanford.edu/ genecards). Among 112 differentially expressed genes with at least twofold changes upon rAAVhTERTC27 treatment, 74 of them were upregulated and 38 were downregulated (Table 2) . These genes could be categorized into nine groups based on their predicted functions, namely those involved in apoptosis, cell cycle, immune response, telomere maintenance, cell adhesion, transport, metabolism, signal transduction and transcription (Figure 5a ). Expression levels of representative genes from various functional categories including dyskeratosis congenital 1 gene (DKC1), 19 target of methylation-induced silencing 1 (TMS1), 20 regulatory factor X-associated protein (RFXAP), 21 
NCAM1
, 22 and SOCS1 23 were validated by semiquantitative RT-PCR. In general, the RT-PCR data were consistent with the microarray data ( Figure 5b and c and Table 2 ). We also performed a similar microarray study on cultured human U87-MG cells transduced with either rAAV-EGFP or rAAV-hTERTC27. Twentyseven genes were found to be differentially expressed with X2-fold changes. Among all these genes, apoptosis was found to be the category, which composed of the highest number of differentially expressed genes (Figure 6a ). The expression levels of four representative apoptosis-related genes, including mitogen-activated protein kinase kinase kinase 7 interacting protein (MAP3K7IP2), 24 lysyl oxidase-like 2 (LOXL2), 25 immunoglobulin heavy constant gamma 1 (IGHG1) 26 and Qk1, 27 were further validated by semiquantitative RT-PCR (Figure 6b and c) . 28, 29 Using this model, we showed that intratumoral injection of rAAV-hTERTC27 dramatically reduces the growth and tumorigenicity of the human glioblastoma U87-MG cells. It also prolongs the median survival of the mice subcutaneously injected with the same cell line. Histological studies show that the antitumor actions of hTERTC27 are likely to be effected by increased apoptosis, necrosis, infiltration of PMNs and reduced angiogenesis. Collectively, these data provide strong evidence that rAAV-hTERTC27 is a novel and potent therapeutic agent for glioblastoma.
AAV is a non-enveloped, single-strand DNA virus, which belongs to the family Parvoviridae. 30 We chose Abbreviations: GBM, glioblastoma multiforme; rAAV-hTERTC27, recombinant adeno-associated virus-human telomerase reverse transcriptase.
hTERTC27 elicits antitumor effect on glioblastoma SSM Ng et al AAV as our gene delivery vector because it offers several advantages over other delivery methods. First, it has not been associated with any known human disease. Second, it can infect a wide range of host cells irrespective of their cell cycle stages. Third, it mediates long-term gene expression. Fourth, when coupled to a strong promoter like the hybrid CMV enhancer/chicken b-actin (CAG) promoter used in this study, it is capable of delivering high levels of transgene expression in a wide variety of cell types. For these reasons, AAV carrying therapeutic genes like angiostatin, 31, 32 herpes simplex virus thymidine kinase (HSV-tK), 33, 34 and interleukin-2 (IL-2) 35 have been employed in the treatment of malignant gliomas with varying degree of success. In the present study, we demonstrated that intratumoral delivery of rAAVhTERTC27, but not rAAV-EGFP, potently inhibits the growth of the glioblastoma cells by more than 80% at 5 weeks post-treatment and significantly prolongs the median survival time of the treated mice by approximately twofold. Histological analyses of the tumor tissues collected from rAAV-hTERTC27-and rAAV-EGFPtreated mice revealed that large areas of the tumor masses are made up of apoptotic and necrotic cells, suggesting that the antitumor actions of hTERTC27 are mediated in part by induction of apoptosis and necrosis.
To investigate the potential mechanisms and gene targets responsible for this phenomenon, we employed DNA microarray to look for genes that are differentially expressed in rAAV-hTERTC27-and rAAV-EGFPtreated GBM xenograft tissues. Our results indicate that several genes related to apoptosis are differentially expressed in the rAAV-hTERTC27-treated tumor tissues. In particular, TMS1, also known as apoptosis-associated speck-like protein containing a CARD (ASC), 36 is the apoptotic gene which displayed the highest fold change after rAAV-hTERTC27 treatment ( þ 4.6-fold). TMS1 enhances caspase-mediated apoptosis and its proapoptotic activity is mediated through the activation of caspase 
9
. 20 It also suppresses carcinogenesis because in human breast cancers, this gene is frequently silenced by aberrant methylation. 37 Thus, it is conceivable that TMS1 upregulation may be responsible in part to the increased apoptosis and hence the inhibition of GBM tumor growth. We have also performed a microarray study in rAAV-hTERTC27-and rAAV-EGFP-infected human glioblastoma U87-MG cells. We found that several apoptosis-related genes, including MAP3K7IP2, LOXL2, IGHG1 and Qk1, were also significantly altered by the rAAV-hTERTC27 treatment. These microarray data are concordant with our histological data showing that rAAV-hTERTC27 could induce marked apoptosis in the tumor tissues (Figure 4c ). Therefore, our findings suggest that apoptosis is one of the major mechanisms that contribute to the growth inhibitory effect of hTERTC27 on GBM cells.
Another candidate target gene, which is of particular interest to us is DKC1, which was downregulated by 4.3-fold in the rAAV-hTERTC27-treated tumor tissues. DKC1 is crucial for telomere maintenance because it is required for the correct intranuclear trafficking of hTERC (or hTR), the RNA component of the hTERT holoenzyme. 19 Mutation of DKC1 leads to a diseased condition known as X-linked dyskeratosis congentita, which is characterized by abnormal pigmentation, bone marrow failure and an increased susceptibility to cancer. 38, 39 Recently, Cayuela et al. 40 has shown in transgenic TERT/ TERC À/À mice that the increased expression of TERT, in the absence of TERC genetic background, leads to reduced tumorigenesis, indicating that the tumor-promoting effects of TERT overexpression require the formation of TERT-TERC complexes. In this regard, we propose that rAAVhTERTC27-mediated downregulation of DKC1 may lead to abnormal processing and/or trafficking of hTERTC, which in turn result in telomere destabilization and eventually senescence and apoptosis in the glioblastoma tissues. Further investigation of this novel hTERTC27-DKC1-hTERTC pathway should yield important information regarding the role of hTERTC27 in glioblastoma cell apoptosis.
Apart from the genes related to apoptosis and telomere maintenance, another group of candidate genes that warrant further studies are those involved in immune responses, because we consistently detected massive infiltration of PMNs in the rAAV-hTERTC27-treated hTERTC27 elicits antitumor effect on glioblastoma SSM Ng et al tumor sections. The candidate immune response genes, which were upregulated by rAAV-hTERTC27 treatment by more than fivefold include: (i) RFXAP, a transcription factor for major histocompatibility complex II; 21 (ii) myeloid cell nuclear differentiation antigen, which is constitutively expressed in cells of myeloid lineage like neutrophils and monocytes; 41 (iii) IL-17, a proinflammatory cytokine which stimulates the secretion of IL-6 and IL-8 in glioblastoma cells. 42 IL-6 is frequently produced in glioblastoma cells, 43 whereas IL-8 is a chemokine, which promotes the directional migration of neutrophils, basophils and T-lymphocytes into the tumor growth area. 44, 45 We speculate that upregulation of these immune response genes may enhance the general immunity of the treated mice to tumor cells by increasing the release of cytokines and infiltration of immune effector cells into the tumor growth areas.
It is worth noting that the PMN infiltrates may account for the tumoricidal effects induced by rAAV-hTERTC27 treatment. PMNs are the most abundant circulating blood leukocytes and their release of soluble chemotactic factors and cytokines can direct the recruitment of both nonspecific and specific immune effector cells with antitumor activities. 46 It has been reported that activated PMNs play a key role in immunosurveillance against several tumors, such as melanoma, lung carcinoma and adenocarcinoma. [47] [48] [49] In cooperation with CD8 þ cells, they are also involved in the cytokine-induced tumor rejections. 50 In this context, it is likely that the immune responses elicited by rAAV-hTERTC27 will be even more prominent in immunocompetent animals.
In conclusion, our data indicate that rAAVhTERTC27 is an effective vector for the gene therapy of glioblastoma. Given that this polypeptide is also capable in inhibiting the proliferation and tumorigenicity of human cervical carcinoma HeLa cells, 12 we anticipate that AAV-mediated transfer of hTERTC27 is adaptable to treating other types of human cancers as well. Further studies on the effect of rAAV-hTERTC27 in immunocompetent animals and characterization of its downstream targets will be instrumental for understanding the anticancer effects of hTERTC27 and for establishing the basis of using this polypeptide in cancer gene therapy.
